Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizanlizumab for cerebral perfusion and oxygenation in adults with sickle cell disease
NL-OMON54849Phase 4Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of crizanlizumab in sickle cell disease (SCD), sponsored by Amsterdam University Medical Center. Started Jan 2022; status: terminated.
02
Drugs
crizanlizumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON54849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54849.